Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

A new study is planned that could someday reshape colon cancer screenings.

Guardant Health Takes Aim at Exact Sciences

Buckeye Partners

Chico's FAS

Earnings and acquisition activity helped make these stocks stand out.

Why Buckeye Partners, Guardant Health, and Chico's FAS Jumped Today

Traders bid up the stock in response to another strong earnings report.

Why Guardant Health Is Soaring Today

Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q1 2019 Results - Earnings Call Transcript

At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.

Guardant Health (GH) to Report Q1 Earnings: What's in Store?

In the latest trading session, Guardant Health (GH) closed at $66.12, marking a -1.9% move from the previous day.

Guardant Health (GH) Stock Sinks As Market Gains: What You Should Know

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Genomic Health

Gilead Sciences

Illumina

Myriad Genetics

Novartis

Invitae

Spark Therapeutics

Pacific Biosciences of California

REGENXBIO

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

Positive comments and favorable industry conditions helped lift several stocks.

Why Guardant Health Jumped Today

Guardant Health Inc is off to a red-hot start to 2019, but one analyst says the rally may be just getting started.

Bank Of America Upgrades Guardant Health On Huge Growth Potential

What went up then came down again is going back up again.

Why Guardant Health Stock Just Popped 10%

The liquid biopsy pioneer has been riding a wave of favorable news lately.

Here's Why Guardant Health Stock Gained 15.1% in March

It can take years for a stock to double -- if it does at all. These three did it in less than three months.

3 Stocks That Are Up More Than 100% in 2019: Guardant Health

How wide are the moats for these healthcare growth stocks?

Illumina vs. Guardant Health

Denali Therapeutics

Vera Bradley

YETI

Here are four stocks to watch with strong price momentum fueled by earnings.

4 Stocks Running On Earnings

Clean Energy Fuels

Oaktree Capital Group

Merger and acquisition news and solid earnings helped give the market a lift.

Why Oaktree Capital Group, Guardant Health, and Clean Energy Fuels Jumped Today

The liquid biopsy leader continues to expand at a rapid pace, and management expects more of the same in 2019.

Guardant Health Is Growing Like Gangbusters

The best player on the biopsy field just isn't getting the attention it deserves.

Why Guardant Health Is the Best Healthcare Stock You've Never Heard Of

The liquid biopsy pioneer has more than doubled since its IPO.

Here's Why Guardant Health Soared 65.2% in February

News for Guardant Health Inc Stock (GH)